Ester Villar
Victoria University, Australia
4 Papers
7 Citations
Ester Villar is an academic researcher from Victoria University, Australia. The author has contributed to research in topics: Cancer & Neoadjuvant therapy. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
Nuria Ribelles,José M. Jerez,Pablo Rodriguez-Brazzarola,Begoña Jimenez,Tamara Diaz-Redondo,Héctor Mesa,Antonia Márquez,Alfonso Sánchez-Muñoz,Bella Pajares,Francisco Carabantes,María José Bermejo,Ester Villar,Maria E. Dominguez-Recio,Enrique Saez,Laura Galvez,Ana Godoy,Leo Franco,Sofia Ruiz-Medina,Irene López,Emilio Alba +19 more
TL;DR: In this paper, the authors developed predictive models for early and late progression to first-line treatment of HR+/HER2-negative metastatic breast cancer, also finding that NLP-based machine learning models are slightly better than predictive models based on manually obtained data.
14
Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.
Begona Jimenez Rodriguez,Ana Isabel Lavado Fernandez,Nuria Ribelles,Pedro Sánchez-Rovira,Luis Vicioso,Martina Alvarez,Vanessa de Luque,Cesar Ramirez Tortosa,Wesley Buckingham,Carl Schaper,Arthur Jeiranian,Naeem Dowidar,Sean Ferree,Ester Villar,Irene Zarcos,Alfonso Sánchez-Muñoz,C González-Hermoso,Casilda Llacer Perez,Aleix Prat,Emilio Alba +19 more
TL;DR: Prosigna has been clinically validated in 2 large randomized studies to predict the risk of distant and late recurrence in HR+/HER2- patients treated with endocrine therapy.
5
Abstract P3-07-15: Prosigna® subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study
R Chica Parrado,Begoña Jiménez-Rodríguez,P. Sanchez Rovira,M. Alvarez,Luis Vicioso,Ana Inés Fernández,V. de Luque,M José Lozano,Ester Villar,Irene Zarcos,Cesar E. Ramirez,C González-Hermoso,Arthur Jeiranian,Naeem Dowidar,Carl Schaper,Wesley Buckingham,Sean Ferree,Nuria Ribelles,I. Rodrigo,Aleix Prat,Emiliano Zamora de Alba +20 more
1
Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients
Angela Santonja,Nuria Ribelles,Begoña Jiménez-Rodríguez,P. Sanchez Rovira,M. Alvarez,Luis Vicioso,A Isabel Fernandez,V. de Luque,C. Fernandez de Sousa,Ester Villar,Irene Zarcos,Cesar E. Ramirez,C González-Hermoso,Arthur Jeiranian,Naeem Dowidar,Carl Schaper,Wesley Buckingham,Sean Ferree,Antonio Núñez Jiménez,Aleix Prat,Emiliano Zamora de Alba +20 more
TL;DR: The results of this study indicate that HER2+ patients with greater correlations to the HER2E subtype have an increased likelihood of response to combination neoadjuvant regimens that included HER2-targeted therapy.
1